Top Page
Argenica Therapeutics Ltd
(Sydney:AGN)
Argenica Therapeutics Ltd (AGN) vs. iShares MSCI Australia ETF (EWA)
Argenica Therapeutics Ltd Business Overview & Revenue Model
Argenica Therapeutics Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.21M | 3.21M | 2.60M | 0.00 | 259.10K | 296.07K |
| Gross Profit | 3.21M | 3.21M | 2.60M | 1.75M | 259.10K | 296.07K |
| EBITDA | 0.00 | 0.00 | -1.90M | -4.81M | -4.09M | -1.33M |
| Net Income | -7.17M | -7.17M | -5.48M | -4.82M | -4.09M | -1.03M |
Balance Sheet | ||||||
| Total Assets | 11.04M | 11.04M | 16.38M | 9.54M | 9.04M | 7.27M |
| Cash, Cash Equivalents and Short-Term Investments | 10.56M | 10.56M | 15.91M | 9.34M | 8.91M | 7.14M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.80M | 3.80M | 2.43M | 1.87M | 735.91K | 425.72K |
| Stockholders Equity | 7.24M | 7.24M | 13.95M | 7.67M | 8.31M | 6.85M |
Cash Flow | ||||||
| Free Cash Flow | -5.70M | -5.70M | -5.06M | -3.30M | -3.36M | -1.05M |
| Operating Cash Flow | -5.70M | -5.70M | -5.06M | -3.30M | -3.36M | -1.05M |
| Investing Cash Flow | 0.00 | 0.00 | 50.00K | -50.00K | 0.00 | 0.00 |
| Financing Cash Flow | 346.90K | 346.90K | 11.63M | 3.73M | 5.13M | 7.85M |
Argenica Therapeutics Ltd Technical Analysis
Argenica Therapeutics Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$41.11M | -5.73 | -67.68% | ― | ― | -5.68% | |
46 Neutral | AU$19.20M | -8.68 | -1651.76% | ― | -100.00% | 2.86% | |
44 Neutral | AU$500.96M | -100.73 | -27.89% | ― | ― | 67.26% | |
44 Neutral | AU$33.06M | -9.09 | -143.71% | ― | 306.88% | ― | |
41 Neutral | AU$87.00M | -5.26 | -42.68% | ― | ― | 63.46% | |
37 Underperform | AU$13.77M | -1.61 | -628.72% | ― | ― | 31.87% |
Argenica Therapeutics Ltd Corporate Events
Argenica Therapeutics has announced the resignation of Non-Executive Chair and Director Dianne Angus, effective at the end of December, after two years on the board during which she helped steer the company through early-stage clinical development, including a successful Phase 2 trial in acute ischaemic stroke and the strategic expansion of its therapeutic pipeline. The board credited Angus with embedding robust governance, risk management and compliance frameworks suited to a clinical-stage biotech and said it has begun searching for a new chair with strong global business development and strategic partnering experience to support Argenica’s planned international growth, signalling an intensifying focus on commercialisation and overseas expansion as the company advances its neuroprotective candidates.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics has announced significant findings from an AI-driven reanalysis of its Phase 2 trial, demonstrating the efficacy of its drug ARG-007 in improving outcomes for severe stroke patients. The analysis revealed that ARG-007 significantly improves functional outcomes and reduces infarct volumes in patients with severe strokes, presenting a substantial commercial opportunity and guiding the design of a precision medicine approach for future trials.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics has announced successful independent validation of its ARG-007 compound in a preclinical study using a rat model of ischemic stroke. The study confirmed that a dose of 325 nmol/kg significantly reduced infarct volume by 47.3%, indicating a strong neuroprotective effect within a specific therapeutic window. These findings, along with previous clinical trial data, will guide future clinical development and dosing strategies for ARG-007 in treating acute ischemic stroke.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics Limited announced the successful passage of all resolutions at its Annual General Meeting held on November 12, 2025. The approval of resolutions, including the adoption of the remuneration report, re-election of a director, and approval of a 10% placement capacity, reflects strong shareholder support and positions the company for continued strategic growth.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics has completed its first trial in acute ischaemic stroke patients, focusing on the safety of its lead product, ARG-007. Despite a fall in share price due to the trial’s top line results, the company remains optimistic about ARG-007’s potential, particularly in specific patient subgroups. The company has secured $1.5 million in grant funding to support further trials and continues to explore ARG-007’s applications in other brain injury indications. Argenica is also strengthening its team to navigate regulatory approvals and expand its clinical trials globally.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics announced the retirement of Mr. Terry Budge, a non-executive director, at the conclusion of their AGM. Mr. Budge has been a pivotal figure since January 2021, contributing significantly to the company’s IPO and the development of ARG-007. His leadership in financial stewardship and capital raising has been instrumental in advancing the company’s clinical trials and development efforts. The company expressed gratitude for his dedication and support.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics has announced the successful completion of its Phase 2 clinical trial for ARG-007, demonstrating safety and tolerability in acute ischemic stroke patients. While the trial did not show a significant overall treatment effect in reducing infarct volumes, a promising efficacy signal was observed in a specific subgroup of high-risk patients. The company plans to advance to a targeted Phase 2b trial, supported by strong functional data and additional funding, to further explore ARG-007’s potential benefits.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics Ltd announced the issuance of 200,000 unquoted equity securities in the form of options expiring in April 2029. This move is part of an employee incentive scheme, which is not intended to be quoted on the ASX. The issuance of these securities reflects the company’s strategy to incentivize and retain talent, potentially impacting its operational dynamics and market positioning.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics Limited announced promising results from its Phase 2 clinical trial of ARG-007, a treatment for acute ischaemic stroke. The trial showed trends of improved cognitive function, independence in daily activities, and quality of life for patients treated with ARG-007 compared to those given a placebo. These findings, although derived from a small sample size, are significant enough to inform the design of a Phase 2b trial. The company plans to advance this next phase in collaboration with its global stroke Clinical Advisory Group and potential pharmaceutical partners, aiming to establish a patient-centered functional endpoint for future regulatory approval.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
Argenica Therapeutics Limited has announced the details of its upcoming Annual General Meeting, scheduled for November 12, 2025, in Perth, Australia. Shareholders are encouraged to participate either in person or by proxy, with voting instructions required by November 10, 2025. The company has opted for electronic distribution of meeting materials, reflecting a modern approach to shareholder communication.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.